Semaglutide as a peptide for weight loss: what the science actually says

Is semaglutide the right peptide pathway for your situation?

Most people searching for semaglutide peptide weight loss are weighing up a specific question: does the science behind this medicine justify trying it, and through what route? That is a sensible way to think about it. Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. GLP-1 is a peptide your gut releases naturally after eating; semaglutide is a lab-made version engineered to last far longer in the body than the natural hormone does. The result is a sustained reduction in appetite and a slower rate of gastric emptying, both of which make eating less considerably easier for most people on treatment.

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity or overweight plus a weight-related condition. At 68 weeks, participants taking semaglutide 2.4mg weekly alongside lifestyle support lost around 15% of body weight on average, compared with roughly 2.4% for the placebo group. That gap is clinically meaningful. Worth knowing, though: the trial ran alongside structured lifestyle advice, which matters when you are thinking about what treatment alone will do. You can read more about how semaglutide works as a peptide on our semaglutide peptide overview page.

The other half of the decision is eligibility. Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above if at least one weight-related health condition is present, such as high blood pressure, raised cholesterol or prediabetes. Whether you sit inside those criteria is the first thing a prescriber will look at, but it is not the only thing. Medical history, current medicines, and anything that might interact with semaglutide all form part of the assessment.

Why Wegovy specifically, not just any semaglutide product?

This is a question our prescribers hear regularly, and it matters. Ozempic also contains semaglutide, but it is licensed solely for managing type 2 diabetes, not for weight management. Rybelsus is oral semaglutide, again licensed for diabetes. Wegovy is the formulation the MHRA has authorised for weight management in adults without diabetes, and it is the one dispensed by UK pharmacies for that purpose. Using a medicine outside its licensed indication carries different clinical considerations, which is one reason a prescriber's assessment is not a box-ticking exercise.

In April 2026, the MHRA also approved a dedicated single-dose 7.2mg Wegovy pen, representing a higher maintenance option for eligible adults, with trials reporting average weight loss of around 20.7% over 72 weeks at that dose. Whether the 7.2mg pen is right for someone is a conversation for later in treatment, not at the start. Treatment always begins at 0.25mg, titrated gradually by the prescriber. If you want to understand how Wegovy fits into the broader picture of semaglutide for weight loss, that page covers the licensed indications in more depth.

One practical note on storage: Wegovy pens need to stay refrigerated between 2°C and 8°C. Many people keep their pen in the fridge door and simply take it out a few minutes before injecting. If you need specifics on travel windows or room-temperature rules, the patient information leaflet is the definitive reference, and our prescribers are available for follow-up questions seven days a week.

What the peptide mechanism means for side effects and long-term use

Because semaglutide works by slowing the gut and suppressing appetite signals, the most common side effects follow logically from that mechanism. Nausea, loose stools, constipation, indigestion and fatigue appear in a significant proportion of people starting treatment or moving up a dose. For most, these settle within a couple of weeks as the body adjusts. Starting at a low dose and titrating slowly is precisely how the licensed schedule is designed, and it is one of the reasons the prescriber controls that process rather than leaving it to the patient.

Less common but more serious is acute pancreatitis. The MHRA flagged this as a known risk in a Drug Safety Update in January 2026. Severe, persistent stomach pain that radiates to the back warrants urgent medical attention. You can report any suspected side effect directly through the MHRA's Yellow Card scheme. Semaglutide is also not recommended during pregnancy, while breastfeeding, or when trying to conceive. Those who are pregnant or planning to become pregnant should speak to their GP before starting or continuing any GLP-1 treatment.

For people asking whether long-term peptide treatment is realistic: NICE's recommendation for semaglutide (Wegovy) notes a maximum treatment duration of two years within its NHS pathway, though clinical circumstances vary. Private treatment follows the licensed indications under ongoing prescriber oversight. If you have questions about what that oversight looks like at our pharmacy, the about page sets out how the service is structured.

Navigating NHS access versus private prescription for semaglutide

Access to Wegovy on the NHS runs through specialist weight management services under NICE's guidance, and waiting lists in many areas are long. NHS eligibility criteria are also stricter than the licensed indications, requiring a weight-related comorbidity and a BMI of 35 or above in most cases (lower thresholds apply for some ethnic backgrounds under UK guidance). That gap between who the medicine is licensed for and who the NHS currently prioritises is why many people explore private prescribing. If you are curious about how Wegovy relates to whether Wegovy is classed as a peptide, that question comes up often and we cover it in detail on a dedicated page.

Private treatment through a GPhC-registered pharmacy is a lawful route provided a qualified prescriber conducts a proper clinical assessment first. No assessment, no prescription: that is not a bureaucratic hurdle but a basic patient safety requirement. If you are already taking Wegovy and thinking about how it fits into your weekly routine, our page on the best day of the week to take Wegovy has practical guidance on building injection day into your schedule. For a broader look at all licensed weight-loss options, including how the range of semaglutide peptides compares across different products and formulations, the weight-loss treatments overview is a good starting point. If you want to understand the official terminology around this medicine, our page explaining the semaglutide peptide name covers how it is classified and why that matters clinically.

If you would like a clinical assessment to see whether semaglutide is appropriate for you, speak to our prescribers via a free consultation. A named GPhC-registered prescriber, not software, reviews every application the same day it is submitted.